Randomized, double-blind, placebo-controlled phase 3 study of paclitaxel {plus minus} napabucasin in pretreated advanced gastric or gastroesophageal junction adenocarcinoma.
Manish A ShahKohei ShitaraFlorian LordickYung-Jue BangNiall C TebbuttJean-Phillippe MetgesKei MuroKeun-Wook LeeLin ShenSergei TjulandinJohn L HaysNaureen StarlingRui-Hua XuKeren SturtzMarilyn FontaineCindy OhEmily BrooksBo XuWei LiChiang J LiLaura BorodyanskyEric Van CutsemPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
Adding napabucasin to paclitaxel did not improve survival in patients with pretreated advanced gastric or GEJ adenocarcinoma. Consistent with previous reports, the safety profile of napabucasin was driven by manageable gastrointestinal events; grade {greater than or equal to}3 diarrhea occurred at a higher frequency with napabucasin plus paclitaxel versus placebo plus paclitaxel.